765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1827763994080837632 |
|---|---|
| author | Robert H Vonderheide Andrew H Ko Danny Khalil Oliver Rosen Robert A Wolff James Francis Samantha Bucktrout Christopher R Cabanski Silvia Boffo Zev A Wainberg Samik Upadhaya Eileen M O’Reilly Mark H O’Hara George Fisher Jamie Arnott Ana Rosa Saez-Ibanez Jay Campbell Ute Dugan Jill O’Donnell-Tormey |
| author_facet | Robert H Vonderheide Andrew H Ko Danny Khalil Oliver Rosen Robert A Wolff James Francis Samantha Bucktrout Christopher R Cabanski Silvia Boffo Zev A Wainberg Samik Upadhaya Eileen M O’Reilly Mark H O’Hara George Fisher Jamie Arnott Ana Rosa Saez-Ibanez Jay Campbell Ute Dugan Jill O’Donnell-Tormey |
| author_sort | Robert H Vonderheide |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:58:31Z |
| format | Article |
| id | doaj.art-b601525223344c068784d6ee00423943 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:58:31Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-b601525223344c068784d6ee004239432023-11-13T03:55:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0765765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trialRobert H Vonderheide0Andrew H Ko1Danny Khalil2Oliver Rosen3Robert A Wolff4James Francis5Samantha Bucktrout6Christopher R Cabanski7Silvia Boffo8Zev A Wainberg9Samik Upadhaya10Eileen M O’Reilly11Mark H O’Hara12George Fisher13Jamie Arnott14Ana Rosa Saez-Ibanez15Jay Campbell16Ute Dugan17Jill O’Donnell-Tormey18Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA1University of California San Francisco, San Francisco, CA, USA1Memorial Sloan Kettering Cancer Center, New York, NY, USA11Akamis Bio, Cambridge, MA, USADepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA10Akamis Bio, Abingdon, Oxfordshire, UKParker Institute for Cancer Immunotherapy, San Francisco, California, USA8Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA3Bristol Myers Squibb, Princeton, NJ, USA13 Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA8Cancer Research Institute, New York, NY, USA2Weill Cornell Medical College, New York, NY, USA2University of Pennsylvania, Philadelphia, PA, USA3Stanford University School of Medicine, Palo Alto, CA, USA7Parker Institute for Cancer Immunotherapy, Chapel Hill, NC, USA10Akamis Bio, Abingdon, Oxfordshire, UK9Cancer Research Institute, New York, NY, USA8Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA9Cancer Research Institute, New York, NY, USA |
| spellingShingle | Robert H Vonderheide Andrew H Ko Danny Khalil Oliver Rosen Robert A Wolff James Francis Samantha Bucktrout Christopher R Cabanski Silvia Boffo Zev A Wainberg Samik Upadhaya Eileen M O’Reilly Mark H O’Hara George Fisher Jamie Arnott Ana Rosa Saez-Ibanez Jay Campbell Ute Dugan Jill O’Donnell-Tormey 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial Journal for ImmunoTherapy of Cancer |
| title | 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial |
| title_full | 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial |
| title_fullStr | 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial |
| title_full_unstemmed | 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial |
| title_short | 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial |
| title_sort | 765 ng 350a a tumor selective anti cd40 agonist expressing therapeutic gemcitabine nab paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma cohort c of the revolution trial |
| work_keys_str_mv | AT roberthvonderheide 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT andrewhko 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT dannykhalil 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT oliverrosen 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT robertawolff 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT jamesfrancis 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT samanthabucktrout 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT christopherrcabanski 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT silviaboffo 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT zevawainberg 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT samikupadhaya 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT eileenmoreilly 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT markhohara 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT georgefisher 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT jamiearnott 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT anarosasaezibanez 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT jaycampbell 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT utedugan 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial AT jillodonnelltormey 765ng350aatumorselectiveanticd40agonistexpressingtherapeuticgemcitabinenabpaclitaxelandipilimumabforuntreatedmetastaticpancreaticadenocarcinomacohortcoftherevolutiontrial |